Axsome Therapeutics

Yahoo Finance • 12 days ago

US Equities Fall in Final 2025 Session; Indexes Still Post Solid Annual Gains

US equity benchmarks fell Wednesday in the final session of 2025 as stock gauges still logged solid PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 12 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Wednesday afternoon with the NYSE Health Care Index dropping 0.5% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 13 days ago

Why Axsome Therapeutics Stock Rocketed Higher to End 2025

Key Points Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD). Auvelity sales soared 69% in Q3. 10 stocks we like b... Full story

Yahoo Finance • 13 days ago

Top Midday Stories: Nvidia Approaches TSMC in Quest to Boost H200 Chip Production; Corcept Faces Setback From FDA on Hypertension Drug

All three major US stock indexes were down in late-morning trading Wednesday as the year winds to a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 13 days ago

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the t... Full story

Yahoo Finance • 13 days ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous syst... Full story

Yahoo Finance • 22 days ago

Dow Jones Futures Due After Two Bullish Days; Palantir, GE Lead 12 Stocks In Buy Zones

Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys. Continue Reading... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy... Full story

Yahoo Finance • 2 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Avenue Therapeutics Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome MIAMI,... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * Oxford Lane Capital Corp. (OXLC [https://seekingalpha.com/symbol/OXLC]) * fuboTV (FUBO [https://se... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 4 months ago

How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress

Axsome Therapeutics recently presented six clinical and real-world neuroscience data posters at the 38th Annual Psych Congress in San Diego, with a focus on major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstruct... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its... Full story

Yahoo Finance • 4 months ago

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company (NYSE: GM), DocGo Inc. (NASDAQ: DCG... Full story

Yahoo Finance • 5 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in t... Full story

Yahoo Finance • 5 months ago

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment

By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by prelimi... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Axsome Therapeutics beats Q2 2025 forecasts

Axsome Therapeutics Inc. (AXSM) reported its second-quarter 2025 earnings, surpassing Wall Street expectations. The company posted an earnings per share (EPS) of -$0.97, outperforming the forecast of -$1.06. Revenues reached $150 million,... Full story

Yahoo Finance • 5 months ago

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading

Axsome Therapeutics Inc (NASDAQ:AXSM [https://www.chartmill.com/stock/quote/AXSM]) reported second-quarter 2025 financial results, delivering revenue that exceeded analyst expectations while narrowing its earnings per share (EPS) loss comp... Full story

Yahoo Finance • 5 months ago

Stocks Set to Open Higher as Investors Bet on Fed Rate Cuts

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story

Yahoo Finance • 6 months ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company... Full story